|
John Mendelsohn (born August 31, 1936) is the past president of The University of Texas MD Anderson Cancer Center in Houston. He is an internationally recognized leader in cancer research. Mendelsohn served as MD Anderson president from 1996 to 2011. When Ronald DePinho became president, he stepped down Sept. 1, 2011. Mendelsohn remains on the faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Also, he is a senior fellow in health and technology at the Baker Institute .〔(【引用サイトリンク】title=Outgoing M.D. Anderson president to join Baker Institute )〕 Mendelsohn was only the third full-time president of MD Anderson. When he arrived, Mendelsohn's focus shifted from his expertise in laboratory research and clinical trials to leading an institution that employs about 18,000 people and serves 100,000 patients yearly, with a budget of more than $3.3 billion. == Background == Mendelsohn earned his bachelor's degree in sciences magna cum laude from Harvard College in 1958. He was the first undergraduate student of James D. Watson, who later won the Nobel Prize in Medicine for identifying the structure of DNA. After spending a year in Scotland as a Fulbright Scholar in biochemistry, Mendelsohn received his medical degree cum laude from Harvard Medical School in 1963. From 1970 to 1985 at the University of California, San Diego, Mendelsohn was founding director of a National Cancer Institute-designated cancer center, which he led from its inception in 1976 until he moved to Memorial Sloan-Kettering Cancer Center. From 1985 to 1996, Mendelsohn chaired the institution's Department of Medicine and was co-head of the Program in Molecular Pharmacology and Therapeutics. He also was professor and vice chairman of medicine at Cornell University Medical College. Mendelsohn was a member the Audit Committee of Enron when it collapsed. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「John Mendelsohn (doctor)」の詳細全文を読む スポンサード リンク
|